Article · Wikipedia archive · Last revised Jul 1, 2026

Pardoprunox

Pardoprunox is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.

Last revised
Jul 1, 2026
Read time
≈ 2 min
Length
373 w
Citations
10
Source
Wikipedia ↗
Pardoprunox
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.206.783
Chemical and physical data
FormulaC12H15N3O2
Molar mass233.271 g·mol−1
3D model (JSmol)
  • Cl.O=C2Oc1c(cccc1N2)N3CCN(C)CC3

Pardoprunox (INN; code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.123[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.1

Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).14 It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.14 Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.45

See also

See also

References

References

  1. Wolf WA (July 2003). "SLV-308. Solvay". Current Opinion in Investigational Drugs. 4 (7): 878–82. PMID 14619412.
  2. "Search of: pardoprunox - List Results - ClinicalTrials.gov".
  3. Bronzova J, Sampaio C, Hauser RA, et al. (March 2010). "Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease". Movement Disorders. 25 (6): 738–746. doi:10.1002/mds.22948. PMID 20198713. S2CID 206241386.
  4. Glennon JC, Van Scharrenburg G, Ronken E, et al. (December 2006). "In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist". Synapse. 60 (8): 599–608. doi:10.1002/syn.20330. PMID 17001660. S2CID 27227349.
  5. Gottwald MD, Aminoff MJ (July 2008). "New frontiers in the pharmacological management of Parkinson's disease". Drugs of Today. 44 (7): 531–45. doi:10.1358/dot.2008.44.7.1217105. PMID 18806903.
Further reading

Further reading